ANVS Annovis Bio, Inc.

NYSE annovisbio.com


$ 2.00 $ -0.14 (-6.45 %)    

Wednesday, 22-Oct-2025 18:50:43 EDT
QQQ $ 604.27 $ -5.89 (-0.96 %)
DIA $ 464.98 $ -3.44 (-0.73 %)
SPY $ 666.76 $ -3.49 (-0.52 %)
TLT $ 92.19 $ 0.06 (0.07 %)
GLD $ 376.01 $ 0.04 (0.01 %)
$ 2.03
$ 2.07
$ 1.98 x 263
$ 2.12 x 12
$ 1.97 - $ 2.15
$ 1.11 - $ 10.54
477,667
na
39.56M
$ 1.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-21-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 03-02-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 07-28-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-03-2021 12-31-2020 10-K
20 11-04-2020 09-30-2020 10-Q
21 07-29-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 03-25-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 annovis-bio-announces-6m-registered-direct-offering-of-common-stock-and-pre-funded-warrants-targeting-october-13-close-for-neurodegeneration-focused-platform

Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneer...

 canaccord-genuity-maintains-buy-on-annovis-bio-maintains-17-price-target

Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:ANVS) with a Buy and maintains $17 price target.

 annovis-bio-highlights-new-buntanetap-form-in-phase-3-alzheimers-trial-extends-patent-protection-into-2040s

Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneer...

 hc-wainwright--co-maintains-buy-on-annovis-bio-lowers-price-target-to-10

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target ...

 annovis-bio-q2-eps-032-beats-040-estimate

Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.40) by ...

 annovis-transfers-full-patent-to-crystal-buntanetap

Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new cr...

 annovis-bio-announces-it-received-nyse-acceptance-letter-granting-the-co-18-month-period-to-maintain-listing

Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneer...

 hc-wainwright--co-maintains-buy-on-annovis-bio-lowers-price-target-to-12

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target ...

Core News & Articles

https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%...

 canaccord-genuity-maintains-buy-on-annovis-bio-lowers-price-target-to-17

Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $26 ...

 annovis-bio-q1-eps-032-beats-036-estimate

Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.36) by ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION